Christopher U. Missling - 15 Jan 2025 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Role: President and CEO, Director
Signature: /s/Christopher Missling, PhD
Issuer symbol: AVXL
Transactions as of: 15 Jan 2025
Net transactions value: $0
Form type: 4
Filing time: 17 Jan 2025, 21:14:04 UTC
Previous filing: 23 Dec 2024
Next filing: 26 Mar 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVXL	Stock Option (Right to Buy)	Award	$0	+166,666		$0.000000	166,000	15 Jan 2025	Common Stock	166,000	$7.54	Direct	F1
transaction	AVXL	Stock Option (Right to Buy)	Award	$0	+125,000		$0.000000	125,000	15 Jan 2025	Common Stock	125,000	$8.57	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 14, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in three equal tranches based on performance milestones, one of which was completion of Phase 2b/3 study for Alzheimer's disease. The performance criteria for this milestone was met with the final publication of all clinical trial data, resulting in vesting of the option as to 166,000 shares.
F2	On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.

Content

On June 14, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in three equal tranches based on performance milestones, one of which was completion of Phase 2b/3 study for Alzheimer's disease. The performance criteria for this milestone was met with the final publication of all clinical trial data, resulting in vesting of the option as to 166,000 shares.

On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.